The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group

Jouen, Théo; Gauthier, Tristan; Azaïs, Henri; Bendifallah, Sofiane; Chauvet, Pauline; Fernandez, H.; Kerbage, Yohan; Lavoué, Vincent; Lecointre, Lise; Mimoun, Camille; Ouldamer, Lobna; Seidler, Stéphanie; Siffert, Marc; Vallin, Anne-Lyse; Spiers, Andrew; Descamps, Philippe; Lacorre, Aymeline; Legendre, Guillaume

doi:10.1016/j.jogoh.2021.102133

“… Chi-Square Test: the Chi-square test is one of the most widely used non-parametric tests, often utilized to test the independence between observed and expected frequencies of one or more attributes in a contingency table. In this work, the Chi-square test was used to identify top significant features given the dependent variable (Y) 36 . …”

Section: Methodsmentioning

confidence: 99%

Machine learning algorithms as new screening approach for patients with endometriosis

Bendifallah

¹

,

Puchar

²

,

Suisse³

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

Endometriosis—a systemic and chronic condition occurring in women of childbearing age—is a highly enigmatic disease with unresolved questions. While multiple biomarkers, genomic analysis, questionnaires, and imaging techniques have been advocated as screening and triage tests for endometriosis to replace diagnostic laparoscopy, none have been implemented routinely in clinical practice. We investigated the use of machine learning algorithms (MLA) in the diagnosis and screening of endometriosis based on 16 key clinical and patient-based symptom features. The sensitivity, specificity, F1-score and AUCs of the MLA to diagnose endometriosis in the training and validation sets varied from 0.82 to 1, 0–0.8, 0–0.88, 0.5–0.89, and from 0.91 to 0.95, 0.66–0.92, 0.77–0.92, respectively. Our data suggest that MLA could be a promising screening test for general practitioners, gynecologists, and other front-line health care providers. Introducing MLA in this setting represents a paradigm change in clinical practice as it could replace diagnostic laparoscopy. Furthermore, this patient-based screening tool empowers patients with endometriosis to self-identify potential symptoms and initiate dialogue with physicians about diagnosis and treatment, and hence contribute to shared decision making.

show abstract

“…2,71,72 Data from the French Society for Pelvic and Gynecological Surgery (SCGP) and the French (FRANCOGYN) Group reveal there are changes in cancer management strategy during the pandemic time and from 181 gynecologic cancer patients, 8 tested positive of Covid-19. 73 Multicenter study from three New York City hospitals also show a similar result, among 302 gynecologic cancer patients, 117 experienced a COVID-19-related treatment modification, 19 have positive Covid-19 result among them 3 are asymptomatic, 11 are having mild symptoms, 3 are hospitalized, and 2 died. 74 Lastly, data from the United Kingdom, Turkey, and Italy show that while maintaining gynecologic cancer treatment during the pandemic time the Covid-19 infection rate is found at a low level, 1/289 is Covid-19 positive and 1 post-operative death suspected of Covid-19 (UK), 2/200 is suspected with Covid-19 but neither was positive for COVID-19 on polymerase chain reaction testing (Turkey), and 1/930 is Covid-19 positive (Italy).…”

Section: Discussionmentioning

confidence: 68%

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Winata

¹

,

Simatupang

²

,

Polim

³

et al. 2022

Preprint

View full text Add to dashboard Cite

ObjectiveCancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer.MethodsSearches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557).ResultsWe accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, p 0.01), (OR 0.26, CI 0.10-0.67 p 0.005), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.51, CI 1.20-1.90, p 0.0004), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 3.06, CI 2.32-4.04, p <0.0001) respectively.ConclusionGynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.SynopsisThis is a systematic review and meta analysis study that presents pooled evidence of outcome among gynecologic cancer patients infected with the Covid-19 infection. We manage to gather 49 studies involving 1994 gynecologic cancer patients with Covid-19, 220967 non cancer patients with Covid-19, 4080990 cancer patients without Covid-19 and 28658 non gynecologic cancer patients with Covid-19 for analysis. Meta analysis shows reduction of Covid-19 death with gynecologic cancer patients vs overall other cancer, lung cancer, and hematologic cancer (OR 0.84, CI 0.72-0.97, p 0.02), (OR 0.52, CI 0.43-0.63, p <0.0001), (OR 0.65, CI 0.49-0.87, p 0.003) respectively. On the contrary, increased risk of Covid-19 death occur to gynecologic cancer patients vs infected non cancer, non Covid cancer patients, and infected breast cancer patients (OR 3.06, CI 2.32-4.04, p <0.0001), (OR 12.21, CI 8.39-17.77, p <0.0001), (OR 1.51, CI 1.20-1.90, p 0.0004) respectively. Analysis from SARS-Cov-2 infection shows lower infection with gynecologic cancer patients vs hematologic cancer cohort (OR 0.71, CI 0.56-0.89, p 0.003). We hope the result of this meta analysis will be useful to providers practicing in cancer centers and tertiary cancer referral hospitals thus better practices and care services given to gynecologic cancer patients infected with / without the Covid-19 during the ongoing global pandemic can be achieved.To our knowledge this is the first systematic review and meta analysis which emphasizes on reporting the outcome of gynecologic cancer patients with the Covid-19 infection. We also found no publication bias across 49 studies we have gathered and used as meta analysis data.

show abstract

“…2,71,72 Data from the French Society for Pelvic and Gynecological Surgery (SCGP) and the French (FRANCOGYN) Group reveal there are changes in cancer management strategy during the pandemic time and from 181 gynecologic cancer patients, 8 tested positive of Covid-19. 73 Multicenter study from three New York City hospitals also show a similar result, among 302 gynecologic cancer patients, 117 experienced a COVID-19-related treatment modi cation, 19 have positive Covid-19 result among them 3 are asymptomatic, 11 are having mild symptoms, 3 are hospitalized, and 2 died. 74 Lastly, data from the United Kingdom, Turkey, and Italy show that while maintaining gynecologic cancer treatment during the pandemic time the Covid-19 infection rate is found at a low level, 1/289 is Covid-19 positive and 1 post-operative death suspected of Covid-19 (UK), 2/200 is suspected with Covid-19 but neither was positive for COVID-19 on polymerase chain reaction testing (Turkey), and 1/930 is Covid-19 positive (Italy).…”

Section: Gynecologic Cancer Vs Hematologic Cancer Discussionmentioning

confidence: 69%

Outcome of Gynecologic Cancer Patients With The Covid-19 Infection : A Systematic Review And Meta Analysis

Winata

¹

,

Simatupang

²

,

Polim

³

et al. 2022

Preprint

0

View full text Add to dashboard Cite

Objective Cancer is comorbidity, which can lead to progressive worsening of Covid-19 with increased mortality. This is a systematic review and meta-analysis to get evidence of adverse outcomes of Covid-19 in gynecologic cancer. Methods Searches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021-19 February 2022). Newcastle-Ottawa Scale tool used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI), random-effects model were presented. This study was registered to PROSPERO (CRD42021256557). Results We accepted 49 studies with (1994 gynecologic cancer with Covid-19). Covid-19 infection was lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56–0.89, p 0.003). Severe Covid and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16–0.80, p 0.01), (OR 0.26, CI 0.10–0.67 p 0.005), (OR 0.52, CI 0.43–0.63, p < 0.0001), (OR 0.65, CI 0.49–0.87, p 0.003) respectively. Increased Covid death is seen in gynecologic cancer vs breast, non-covid cancer, and non-cancer covid (OR 1.51, CI 1.20–1.90, p 0.0004), (OR 12.21, CI 8.39–17.77, p < 0.0001), (OR 3.06, CI 2.32–4.04, p < 0.0001) respectively. Conclusion Gynecologic cancer had increased Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer had lowered Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. Lack of age and comorbidities stratification due to limited data were limitations. These findings may aid health policies and services during the ongoing global pandemic.

show abstract

The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SCGP and the FRANCOGYN group

Cited by 17 publications

References 5 publications

Machine learning algorithms as new screening approach for patients with endometriosis

Machine learning algorithms as new screening approach for patients with endometriosis

The Outcome of Gynecologic Cancer Patients With Covid-19 Infection: A Systematic Review And Meta-Analysis

Outcome of Gynecologic Cancer Patients With The Covid-19 Infection : A Systematic Review And Meta Analysis

Contact Info

Product

Resources

About